No profile data available.
Voyager Therapeutics, Inc. (VYGR) is a healthcare company in the brain and nerve treatment drugs industry, based in Lexington, United States, with about 141 full-time employees.
It reported revenue of $40.37 million for fiscal year 2025, down 49.5% from fiscal year 2024, and net income of -$119.72 million. Its market capitalization was $150.96 million as of October 2, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 2, 2026.
, a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease.
Voyager Therapeutics reported $40.37 million in revenue for fiscal year 2025, down 49.5% from $80.00 million in fiscal year 2024.
$150.96 million as of October 2, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include PepGen Inc. (PEPG), Acumen Pharmaceuticals, Inc. (ABOS), Minerva Neurosciences, Inc. (NERV), Anavex Life Sciences Corp. (AVXL).